According to the latest report by IMARC Group, titled “Asthma Therapeutics Market Report by Drug Class (Anti-Inflammatory Drugs, Bronchodilators, Combination Therapies), Product Type (Inhalers, Nebulizers), Treatment Type (Quick-Relief Medications, Long-Term Asthma Control Medications), Route of Administration (Inhalation, Oral, Parenteral), and Region 2025-2033,” the global asthma therapeutics market reached a value of USD 18.8 Billion in 2024. Asthma therapeutics are pharmaceutical drugs utilized in the treatment of asthma, which is characterized by breathlessness and wheezing attacks triggered by indoor and outdoor causative agents. These drugs expand the passageway of the lungs and allow air movement to improve breathing. Some of the commonly prescribed asthma therapeutics include bronchodilator drugs, including long-acting beta-agonists (LABA), corticosteroids, immunomodulators, methylxanthine and leukotriene modifiers.
Global Asthma Therapeutics Market Trends:
The increasing incidences of asthma and other respiratory diseases, along with the rapidly improving diagnostic technologies, represent one of the key factors augmenting the asthma therapeutics market growth. Besides this, extensive research and development (R&D) activities undertaken by the leading players to develop advanced asthma therapeutics and the growing healthcare expenditures are also contributing to the growth of the market. Moreover, governing authorities of numerous countries are introducing campaigns to spread awareness about the availability of effective therapeutics among individuals. This, in confluence with the introduction of combination therapies for treating respiratory diseases, is positively influencing the demand for asthma therapeutics across the globe. Looking forward, the market value is projected to reach USD 22.1 Billion by 2033, expanding at a CAGR of 1.8% during the forecast period (2025-2033).
Market Summary:
Report Features | Details |
---|---|
Base Year of the Analysis | 2024 |
Historical Period | 2019-2024 |
Forecast Period | 2025-2033 |
Units | Billion USD |
Segment Coverage | Drug Class, Product Type, Treatment Type, Route of Administration, Region |
Region Covered | Asia Pacific, Europe, North America, Latin America, Middle East and Africa |
Countries Covered | United States, Canada, Germany, France, United Kingdom, Italy, Spain, Russia, China, Japan, India, South Korea, Australia, Indonesia, Brazil, Mexico |
Companies Covered | AstraZeneca PLC, Abbott Laboratories, Amgen Inc., Biogen Inc., Boehringer Ingelheim International GmbH, F. Hoffmann-La Roche Ltd., GlaxoSmithKline Plc, Merck Sharp & Dohme Corp., Novartis International AG, Sunovion Pharmaceuticals Inc. and Teva Pharmaceutical Industries Ltd. |
Customization Scope | 10% Free Customization |
Post-Sale Analyst Support | 10-12 Weeks |
Delivery Format | PDF and Excel through Email (We can also provide the editable version of the report in PPT/Word format on special request) |
About Us:
IMARC Group is a leading market research company that offers management strategy and market research worldwide. We partner with clients in all sectors and regions to identify their highest-value opportunities, address their most critical challenges, and transform their businesses.
IMARC’s information products include major market, scientific, economic and technological developments for business leaders in pharmaceutical, industrial, and high technology organizations. Market forecasts and industry analysis for biotechnology, advanced materials, pharmaceuticals, food and beverage, travel and tourism, nanotechnology and novel processing methods are at the top of the company’s expertise.
Contact Us:
IMARC Group
30 N Gould St, Ste R
Sheridan, WY 82801, USA
Email: sales@imarcgroup.com
Americas: +1 631 791 1145 | Europe & Africa: +44-753-713-2163 | Asia: +91-120-433-0800